Pancreatic lipase inhibitory activity of monogalactosyldiacylglycerols isolated from the freshwater microalga Chlorella sorokiniana | Zendy

Arjun H. Banskota | Zendy; Aaron Steevensz | Zendy; Roumiana Stefanova | Zendy; Sandra Sperker | Zendy; Ronald Melanson | Zendy; Jane A. Osborne | Zendy; Stephen J. B. O’Leary | Zendy; Jeremy E. Melanson | Zendy

Open Access

Pancreatic lipase inhibitory activity of monogalactosyldiacylglycerols isolated from the freshwater microalga Chlorella sorokiniana

Author(s) -

Arjun H. Banskota,

Aaron Steevensz,

Roumiana Stefanova,

Sandra Sperker,

Ronald Melanson,

Jane A. Osborne,

Stephen J. B. O’Leary,

Jeremy E. Melanson

Publication year - 2015

Publication title -

journal of applied phycology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.681

H-Index - 108

eISSN - 1573-5176

pISSN - 0921-8971

DOI - 10.1007/s10811-015-0558-9

Subject(s) - chlorella sorokiniana , lipase , triacylglycerol lipase , chlorella , biology , biochemistry , rhizopus oryzae , food science , galactolipids , algae , enzyme , chemistry , chromatography , botany , fermentation , chloroplast , gene

Chemical investigation of the freshwater microalga Chlorella sorokiniana led to the isolation of a monogalactosyldiacylglycerol (MGDG)-rich fraction possessing dose-dependent inhibitory activity against pancreatic lipase activity. The MGDG-rich fraction contains 12 MGDGs identified by LC/HRMS analysis. Among them, three MGDGs were new compounds, namely, (2S)-1-O-(7Z,10Z-hexadecadienoyl)-2-O-(7Z,10Z,13Z-hexadecatrienoyl)-3-O-\u3b2-D-galactopyranosylglycerol (1), (2S)-1-O-linoleoyl-2-O-(7Z,10Z-hexadecadienoyl)-3-O-\u3b2-D-galactopyranosylglycerol (6), and (2S)-1-O-oleoyl-2-O-(7Z,10Z-hexadecadienoyl)-3-O-\u3b2-D-galactopyranosylglycerol (8). The major galactolipids were isolated by semipreparative HPLC and tested for their effect toward pancreatic lipase inhibitory activity. All the tested MGDGs showed significant reduction of pancreatic lipase activity indicating possible beneficial use for management of lipase-related disorders such as obesity.Peer reviewed: YesNRC publication: Ye

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research